BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Greuel A, Trezzi JP, Glaab E, Ruppert MC, Maier F, Jäger C, Hodak Z, Lohmann K, Ma Y, Eidelberg D, Timmermann L, Hiller K, Tittgemeyer M, Drzezga A, Diederich N, Eggers C. GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Mov Disord 2020;35:2201-10. [PMID: 32853481 DOI: 10.1002/mds.28225] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 de Natale ER, Wilson H, Politis M. Dopaminergic molecular imaging in familial and idiopathic Parkinson's disease. Neuroimaging in Parkinson�s Disease and Related Disorders 2023. [DOI: 10.1016/b978-0-12-821651-4.00016-6] [Reference Citation Analysis]
2 Verghese JP, de Natale ER, Politis M. Functional MRI in familial and idiopathic PD. Neuroimaging in Parkinson�s Disease and Related Disorders 2023. [DOI: 10.1016/b978-0-12-821651-4.00007-5] [Reference Citation Analysis]
3 Hou Y, Feng F, Zhang L, Ou R, Lin J, Gong Q, Shang H. Disrupted topological organization of resting-state functional brain networks in Parkinson's disease patients with glucocerebrosidase gene mutations. Neuroradiology 2022. [PMID: 36269334 DOI: 10.1007/s00234-022-03067-9] [Reference Citation Analysis]
4 Prange S, Theis H, Banwinkler M, van Eimeren T. Molecular Imaging in Parkinsonian Disorders—What’s New and Hot? Brain Sciences 2022;12:1146. [DOI: 10.3390/brainsci12091146] [Reference Citation Analysis]
5 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations and Parkinson disease. J Neural Transm (Vienna) 2022. [PMID: 35932311 DOI: 10.1007/s00702-022-02531-3] [Reference Citation Analysis]
6 Rossi M, Castillo-Torres SA, Merello M. Early motor response to dopamine replacement therapy in Parkinson's disease patients carrying GBA variants. J Neurol Sci 2022;440:120354. [PMID: 35907343 DOI: 10.1016/j.jns.2022.120354] [Reference Citation Analysis]
7 Smith LJ, Bolsinger MM, Chau K, Gegg ME, Schapira AHV. The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.. [DOI: 10.1101/2022.06.01.494130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ghatti S, Yoon E, Lopez G, Ehrlich D, Horovitz SG. Imaging and genetics in Parkinson's disease: assessment of the GBA1 mutation. J Neurol 2022. [PMID: 35604467 DOI: 10.1007/s00415-022-11181-0] [Reference Citation Analysis]
9 Shen J, Amari N, Zack R, Skrinak RT, Unger TL, Posavi M, Tropea TF, Xie SX, Van Deerlin VM, Dewey RB Jr, Weintraub D, Trojanowski JQ, Chen-Plotkin AS. Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease. Ann Neurol 2022. [PMID: 35593028 DOI: 10.1002/ana.26410] [Reference Citation Analysis]
10 Filippi M, Balestrino R, Basaia S, Agosta F. Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review. Mov Disord 2022. [PMID: 35521899 DOI: 10.1002/mds.29047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tönges L, Buhmann C, Klebe S, Klucken J, Kwon EH, Müller T, Pedrosa DJ, Schröter N, Riederer P, Lingor P. Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice. J Neural Transm. [DOI: 10.1007/s00702-022-02498-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Müller T. Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson's disease: are we on the right track? Expert Rev Mol Diagn 2022;:1-7. [PMID: 35400295 DOI: 10.1080/14737159.2022.2065198] [Reference Citation Analysis]
13 Smith L, Schapira AHV. GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells 2022;11:1261. [DOI: 10.3390/cells11081261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
14 Shen J, Amari N, Zack R, Skrinak RT, Unger TL, Posavi M, Tropea TF, Xie SX, Van Deerlin VM, Dewey RB, Weintraub D, Trojanowski JQ, Chen-plotkin AS. Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson’s Disease.. [DOI: 10.1101/2022.03.16.22272456] [Reference Citation Analysis]
15 Steidel K, Ruppert MC, Palaghia I, Greuel A, Tahmasian M, Maier F, Hammes J, van Eimeren T, Timmermann L, Tittgemeyer M, Drzezga A, Pedrosa D, Eggers C. Dopaminergic pathways and resting-state functional connectivity in Parkinson's disease with freezing of gait. Neuroimage Clin 2021;32:102899. [PMID: 34911202 DOI: 10.1016/j.nicl.2021.102899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Müller T. GOCOVRI® (amantadine) extended-release capsules in Parkinson's disease. Neurodegener Dis Manag 2021. [PMID: 34918543 DOI: 10.2217/nmt-2021-0028] [Reference Citation Analysis]
17 Chung SJ, Lee PH, Sohn YH, Kim YJ. Glucocerebrosidase Mutations and Motor Reserve in Parkinson's Disease. J Parkinsons Dis 2021;11:1715-24. [PMID: 34459414 DOI: 10.3233/JPD-212758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yang F, Chen S, Qu Z, Wang K, Xie X, Cui H. Genetic Liability to Sedentary Behavior in Relation to Stroke, Its Subtypes and Neurodegenerative Diseases: A Mendelian Randomization Study. Front Aging Neurosci 2021;13:757388. [PMID: 34867285 DOI: 10.3389/fnagi.2021.757388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, Goldstein O, Kestenbaum M, Cedarbaum JM, Mabrouk OS, Fraser KB, Shirvan JC, Orr-Urtreger A, Mirelman A, Thaler A. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. Mov Disord 2021. [PMID: 34550621 DOI: 10.1002/mds.28792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
20 Meles SK, Oertel WH, Leenders KL. Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease. Mol Med 2021;27:111. [PMID: 34530732 DOI: 10.1186/s10020-021-00327-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
21 Pachi I, Koros C, Simitsi AM, Papadimitriou D, Bougea A, Prentakis A, Papagiannakis N, Bozi M, Antonelou R, Angelopoulou E, Beratis I, Stamelou M, Trapali XG, Papageorgiou SG, Stefanis L. Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers. Parkinsonism Relat Disord 2021;91:1-8. [PMID: 34425330 DOI: 10.1016/j.parkreldis.2021.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Müller T. View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track? Biologics 2021;15:307-16. [PMID: 34349499 DOI: 10.2147/BTT.S267281] [Reference Citation Analysis]
23 Menozzi E, Schapira AHV. Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Front Neurol 2021;12:694764. [PMID: 34248830 DOI: 10.3389/fneur.2021.694764] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
24 Prasuhn J, Brüggemann N. Genotype-driven therapeutic developments in Parkinson's disease. Mol Med 2021;27:42. [PMID: 33874883 DOI: 10.1186/s10020-021-00281-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
25 Hirano S. Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson's disease. Mol Med 2021;27:40. [PMID: 33858320 DOI: 10.1186/s10020-021-00301-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
26 Müller T, Mueller BK, Riederer P. Perspective: Treatment for Disease Modification in Chronic Neurodegeneration. Cells 2021;10:873. [PMID: 33921342 DOI: 10.3390/cells10040873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
27 Ruppert MC, Greuel A, Freigang J, Tahmasian M, Maier F, Hammes J, van Eimeren T, Timmermann L, Tittgemeyer M, Drzezga A, Eggers C. The default mode network and cognition in Parkinson's disease: A multimodal resting-state network approach. Hum Brain Mapp 2021;42:2623-41. [PMID: 33638213 DOI: 10.1002/hbm.25393] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
28 Zhang Y, Li J, Zhang X, Song D, Tian T. Advances of Mechanisms-Related Metabolomics in Parkinson's Disease. Front Neurosci 2021;15:614251. [PMID: 33613180 DOI: 10.3389/fnins.2021.614251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]